President Trump's nomination of former Fed Governor Kevin Warsh to lead the central bank has ignited market speculation over the future path of interest rates, with analysts divided on whether his leadership would mean more cuts or a return to hawkish restraint.
President Trump's nomination of former Fed governor Kevin Warsh to lead the central bank has sparked immediate concerns on Wall Street about political influence over monetary policy, setting the stage for a contentious Senate confirmation battle.
The FDA clearance of Spectrum Dynamics' Veritas.AI platform marks a significant step forward for nuclear imaging, promising to cut scan times in half and enhance image clarity for critical applications like cancer theranostics.
The consumer goods giant reports resilient Q4 2025 results, beating expectations despite market headwinds, and unveils a comprehensive new strategy focused on omnichannel demand, premiumization, and AI-driven efficiency to drive growth through 2030.
A dramatic rally in gold and silver prices came to an abrupt halt on Friday, with futures tumbling sharply amid a broader market sell-off and warnings of unsustainable volatility.
The U.S. labor market faced its toughest year since the pandemic in 2025, with layoffs soaring to 1.2 million. Economists warn of an 'uncomfortably slow' rebound in 2026, leaving job seekers navigating a landscape of fierce competition and hiring freezes.
A blistering rally in gold and silver came to an abrupt halt Friday, with prices tumbling sharply as market volatility surged and analysts warned the historic run may be entering a precarious phase.
President Donald Trump has nominated Kevin Warsh, a former Federal Reserve governor and longtime critic of its recent policy, to be the next chair of the central bank, setting up a potential shift in monetary policy amid ongoing tensions over interest rates and Fed independence.
A bold congressional proposal to cap credit card interest rates at 10% is drawing sharp criticism from Wall Street and raising fundamental questions about the future profitability of card issuers like American Express.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Despite posting strong quarterly earnings, ServiceNow (NOW) tumbled for a third consecutive session as investor focus shifts to the long-term disruptive potential of AI on the traditional SaaS subscription model.
